Abstract
Several lines of evidence indicate that serum paraoxonase 1 (PON1) acts as an important guardian against cellular damage from oxidized lipids in plasma membrane, in low-density lipoprotein (LDL), against bacterial endotoxin and against toxic agents such as pesticide residues including organophosphates. In circulation, the high-density lipoprotein (HDL)-associated PON1 has the ability to prevent the formation of proinflammatory oxidized phospholipids. These oxidized phospholipids negatively regulate the activities of the HDL-associated PON1 and several other anti-inflammatory factors in HDL. During the acute phase response in rabbits, mice, and humans, there appears to be an increase in the formation of these oxidized lipids that results in the inhibition of the HDL-associated PON1 and an association of acute phase proteins with HDL that renders HDL proinflammatory. Low serum HDL is a risk factor for atherosclerosis and attempts are directed toward therapies to improve the quality and the relative concentrations of LDL and HDL. Apolipoprotein A-I (apoA-I) has been shown to reduce atherosclerotic lesions in laboratory animals. ApoA-I, however, is a large protein and needs to be administered parenterally, and it is costly. We have developed apoA-I mimetic peptides that are much smaller than apoA-I, and much more effective in removing the oxidized phospholipids and other oxidized lipids. These mimetic peptides improve LDL and HDL composition and function and reduce lesion formation in animal models of atherogenesis. Following is a brief description of some of the HDL mimetic peptides that can improve HDL and the effect of the peptide on PON1 activity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Anantharamaiah GM, Jones JL, Brouillette CG, et al. 1985. Studies of synthetic peptide analogs of amphipathic helix I: structure of peptide/DMPC complexes. J Biol Chem 260:10248–10255.
Badimon JA, Badimon L, Fuster V 1990. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85:1234–1241.
Berliner JA, Watson AD 2005. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 353:9–12.
Datta G, Chaddha M, Hama S, et al. 2001. Effects of increasing hydrophobicity on the physical–chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 42:1096–1104.
Datta G, Epand RF, Epand RM, et al. 2004. Aromatic residue position on the nonpolar face of class a amphipathic helical peptides determines biological activity. J Biol Chem. 18;279:26509–26517.
Forte, TM, et al. 2002. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis susceptible mice. J Lipid Res 43:477–485.
Gargalovic PS, Imura M, Zhang B, et al. 2006. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci 103:12741–12746.
Li X, Chyu K-Y, Faria JR, et al. 2004. Differential effects of apolipoprotein A-I mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110:1701–1705.
Navab M, Anantharamaiah GM, Hama S, et al. 2002. Oral administration of an apoA-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105:290–292.
Navab M, Anantharamaiah GM, Reddy ST, et al. 2004. Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109:3215–3220.
Navab M, Anantharamaiah GM, Hama S, et al. 2005a. D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25:1426–1432.
Navab M, Anantharamaiah GM, Reddy ST, et al. 2005b. An oral apoJ peptide renders HDL anti-inflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 25:1932–1937.
Navab M, Anantharamaiah GM, Reddy ST, et al. 2005c. Oral small peptides render HDL anti-inflammatory in mice and monkeys and reduce atherosclerosis in apoE null mice. Circ Res 97:524–532.
Navab M, Anantharamaiah GM, Reddy ST, et al. 2005d. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 25:1325–1331.
Navab M, Hama-Levy S, Van Lenten BJ, et al. 1997. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 15;99:2005–2019.
Nissen SE, Tsunoda T, Tuzcu EM, et al. 2003. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 290:2292–2300.
Plump AS, Scott CJ, Breslow JL 1994. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 91:9607–9611.
Tardif JC, Grégoire J, L’Allier PL, et al. 2007. Effect of rHDL on atherosclerosis-safety and efficacy (ERASE) investigators. JAMA. 18;297:1675–1682.
Van Lenten BJ, Wagner AC, Navab M, et al. 2007. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res 48:2344–2353.
Venkatachalapathi YV, Phillips MC, Epand RM, et al. 1993. Effect of end group blockage on the properties of a class A amphipathic helical peptide. Proteins Struct Funct Genet 15:349–359.
Yancey PG, Bielicki JK, Lund-Katz S, et al. 1995. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 34:7955–7965. PII S1050-1738(08)00002-9 TCM
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press, a part of Springer Science+Business Media, LLC
About this paper
Cite this paper
Vakili, L. et al. (2010). The Effect of HDL Mimetic Peptide 4F on PON1. In: Reddy, S. (eds) Paraoxonases in Inflammation, Infection, and Toxicology. Advances in Experimental Medicine and Biology, vol 660. Humana Press. https://doi.org/10.1007/978-1-60761-350-3_15
Download citation
DOI: https://doi.org/10.1007/978-1-60761-350-3_15
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-349-7
Online ISBN: 978-1-60761-350-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)